Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres

Grant M, Haydon A, Au L, Wilkins S, Oliva K, Segelov E, Antill Y, Carne P, Ranchod P, Polglase A, Farmer C, Chin M, Wale R, Simpson P, Bell S, Skinner S, McMurrick P, Shapiro J

(2018), Int J Surg, 51, 71-75

DOI: 10.1016/j.ijsu.2018.01.020

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors

Ameratunga M, Ch»nard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, Aversa C, Ingles Garces A, Ang JE, Banerji U, Kaye S, Gan H, Doger B, Moreno V, de Bono J, Lopez J

(2018), Eur J Cancer, 89, 56-63

DOI: 10.1016/j.ejca.2017.11.012

Anti-angiogenic therapy for high-grade glioma

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M

(2018), Cochrane Database Syst Rev, 11, CD008218

DOI: 10.1002/14651858.CD008218.pub4

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit

Sundar R, Custodio A, Petruckevich A, Ch»nard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye SB, Tunariu N, Banerji U, de Bono J, Lopez J

(2018), Clin Oncol, 30(3), 185-191

DOI: 10.1016/j.clon.2017.11.011

Personalized cancer immunotherapy: Today's challenge and tomorrow's promise

Ameratunga M, Xu W, Lopez J

(2018), J Immunother Precis Oncol, 1, 56-67

DOI: 10.4103/JIPO.JIPO_13_18

CNS cancer immunity cycle and strategies to target this for glioblastoma

Ameratunga M, Coleman N, Welsh L, Saran F, Lopez J

(2018), Oncotarget, 9(32), 22802-22816

DOI: 10.18632/oncotarget.24896

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiri»r M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT

(2018), Eur J Cancer, 101, 55-61

DOI: 10.1016/j.ejca.2018.06.003

A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting

Ameratunga M, Miller D, Ng W, Wada M, Gonzalvo A, Cher L, Gan HK

(2018), J Clin Neurosci, 56, 127-130

DOI: 10.1016/j.jocn.2018.06.032

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

Ingles Garces AH, Ang JE, Ameratunga M, Ch»nard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U

(2018), Eur J Cancer, 104, 32-38

DOI: 10.1016/j.ejca.2018.08.019

The value of participating in clinical trials: the whole is greater than the sum of its parts

Zalcberg JR, Friedlander M

(2018), Med J Aust, 209(10), 424-425

DOI: 10.5694/mja17.01266

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

Moloney M, Faulkner D, Link E, Rischin D, Solomon B, Lim AM, Zalcberg JR, Jefford M, Michael M

(2018), Cancer Chemother Pharmacol, 82(5), 865-876

DOI: 10.1007/s00280-018-3679-4

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW

Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C

(2018), J Gastroenterol Hepatol, 33(4), 814-824

DOI: 10.1111/jgh.14007

Biosimilars are coming: ready or not

Zalcberg J

(2018), Intern Med J, 48(9), 1027-1034

DOI: 10.1111/imj.14033

Rationale, Opportunities, and Reality of Biosimilar Medications

Zalcberg JR

(2018), N Engl J Med, 379(7), 694

DOI: 10.1056/NEJMc1808348

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

Goey KKH, Sørbye H, Glimelius B, Adams RA, Andr» T, Arnold D, Berlin JD, Bodoky G, de Gramont A, DÃaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M

(2018), Eur J Cancer, 100, 35-45

DOI: 10.1016/j.ejca.2018.05.010

Telehealth

Sabesan S, Zalcberg J

(2018), N Engl J Med, 378(4), 402

DOI: 10.1056/NEJMc1715239

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD)

(2018), J Natl Cancer Inst, 110(6), 638-648

DOI: 10.1093/jnci/djx253

High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy

Chandrasekara S, Davis S, Thomson P, Haydon A

(2018), Asia Pac J Clin Oncol, 14(5), e442-7

DOI: 10.1111/ajco.12846

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudá R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM

(2017), Lancet, 390(10103), 1645-53

DOI: 10.1016/S0140-6736(17)31442-3

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS

(2017), Br J Cancer, 116(12), 1558-63

DOI: 10.1038/bjc.2017.142

5 6 7 8 9